GlassScriptPhysician profile
Peter R Dumas
NPI 1043245665
$8,162.44
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,048 · 2020: $506 · 2021: $1,238 · 2022: $1,895 · 2023: $2,344 · 2024: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,027.78 | 2019-2023 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $811.06 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $698.14 | 2019-2023 | Simponi, Remicade, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $606.51 | 2019-2023 | Entyvio, Gattex |
| Celgene Corporation | $339.71 | 2021-2023 | Zeposia |
| Pfizer INC. | $302.49 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $208.22 | 2019-2023 | Linzess |
| Allergan, INC. | $192.49 | 2019 | |
| Genzyme Corporation | $192.40 | 2023 | |
| Vivus LLC | $191.38 | 2019-2023 | Pancreaze |
| Braintree Laboratories, INC. | $156.42 | 2019-2023 | Suflave, Sutab |
| Axonics, INC. | $136.82 | 2023 | Axonics |
| Intercept Pharmaceuticals, INC. | $128.72 | 2019 | |
| Medtronic, INC. | $121.18 | 2022 | |
| Ucb, INC. | $112.53 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $103.68 | 2024 | Dupixent |
| Shionogi INC | $102.16 | 2019 | |
| Ferring Pharmaceuticals INC. | $76.44 | 2019-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $74.67 | 2021-2022 | |
| Fujifilm Healthcare Americas Corporation | $72.28 | 2023 | Fujifilm |
| Redhill Biopharma INC. | $67.54 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Regeneron Healthcare Solutions, INC. | $66.45 | 2022-2023 | Dupixent |
| Medtronic USA, INC. | $63.01 | 2019 | |
| Amgen INC. | $48.58 | 2023 | Avsola, Amjevita |
| Qol Medical, LLC | $45.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.21 | 2022-2023 | Dificid |
| Ardelyx, INC. | $35.51 | 2023 | Ibsrela |
| Mauna Kea Technologies, INC. | $27.37 | 2024 | |
| Pharmacosmos Therapeutics INC. | $24.80 | 2022 | |
| Lilly USA, LLC | $22.88 | 2023 | |
| Covidien LP | $19.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $15.53 | 2021 | |
| Gilead Sciences, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dumas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.